Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.
The safety of gadolinium (Gd-benzyloxypropionictetra-acetate [BOPTA] dimeglumine) infusion was evaluated in 32 patients with severe or moderate chronic renal failure in a prospective, randomized, double-blind, placebo-controlled study. Renal failure was defined as severe if creatinine clearance was between 10 and 29 mL/min, and as moderate if creatinine clearance was between 30 and 60 mL/min. Serum creatinine level and 24-hour urine samples for creatinine clearance were followed up serially for 7 days after the administration of either gadolinium (Gd-BOPTA dimeglumine), 0.2 mmol/kg, or a saline infusion. No patient experienced a significant change in renal function, defined as an increase in serum creatinine level greater than 0.5 mg/dL more than baseline, and no patient required hospitalization or dialysis during the study period. Gadolinium (Gd-BOPTA dimeglumine) appears to be well tolerated in patients with moderate to severe renal failure.
Townsend
R R
RR
University of Pennsylvania, Philadelphia, PA 19104, USA. townsend@mail.med.upenn.edu
Cohen
D L
DL
Katholi
R
R
Swan
S K
SK
Davies
B E
BE
Bensel
K
K
Lambrecht
L
L
Parker
J
J
D003287:Contrast Media; D004311:Double-Blind Method; D005682:Gadolinium; D006801:Humans; D007262:Infusions, Intravenous; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications*
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium